Finding the "Secret Sauce" For Personalized, Functional Insulin-Producing Cells

The Salk technology begins with induced pluripotent stem cells (iPSCs), a technique where tissue from a patient is reprogrammed into other types of cells, such as from the pancreas. This step yields the pre-beta cells, which produce insulin but are not yet functional. While several research groups reached this juncture, the road forward to functional cells was not clear.

“Pancreatic beta cells must be able to do two things to work effectively: respond to glucose and produce insulin,” says Evans. “No one had been able to figure out how to make pancreatic cells from human patients that can do both until now.”

Eiji Yoshihara, first author and Salk research associate, together with Evans and Salk colleagues, closely studied the basic biology of a beta cell and uncovered several molecular switches, called transcription factors, that were switched off but might control the transition to a fully functional state. The “secret sauce,” the Salk team found, was one particular switch the Evans lab had studied for years for its role in cell signaling. This protein switch, called ERR-gamma, turned out to be crucial to awakening silent beta-like cells that could now respond to glucose and release insulin accordingly. The team found that when the matured beta cells were transplanted into type 1 diabetic mice, the procedure quickly rescued their diabetes.

“This advance will result in a better controlled insulin response than currently available treatments,” says Michael Downes, co-senior author and a Salk senior staff scientist. He adds that the team’s technique is an easy, fast and inexpensive way to make transplantable human pancreatic beta cells in a dish that genetically match patients. The researchers hope to move to human trials within the next few years.